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Abstract
In hemophilia A and B, analysis of the F8 and F9 gene variants enables carrier and
prenatal diagnosis and prediction of risk for the development of inhibitors. The
PedNet Registry collects clinical, genetic, and phenotypic data prospectively on
more than 2000 children with hemophilia. The genetic reports of F8/F9 gene var-
iants were classified uniformly to Human Genome Variation Society nomenclature
and reevaluated using international population‐ and disease‐specific databases, lit-
erature survey and, where applicable, computational predictive programs. We re-
port 88 novel variants in the F8 and F9 genes, 80 fulfilling criteria for Class 5
(pathogenic), six for Class 4 (likely pathogenic) and two fulfilling criteria for Class 3
(variant of unknown significance) of the American College of Medical Genetics and
Genomics/Association for Molecular Pathologyguidelines together with information
on the respective phenotype and inhibitor formation. The study highlights the need
to reevaluate and update earlier genetic reports in hemophilia both locally but also
in variant databases in light of changed nomenclature and new guidelines.
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1 | INTRODUCTION
Hemophilia A and B are X‐linked recessive congenital bleeding dis-
orders caused by pathogenic variants in, respectively, the F8 or F9
gene. Hemophilia A, caused by lack or dysfunction of the plasma
protein Factor VIII (FVIII), affects about 1/5000 males, while he-
mophilia B, caused by lack or dysfunction of Factor IX (FIX), affects
approximately 1/30,000 males (Mannucci & Tuddenham, 2001).
Depending on the residual clotting activity in plasma levels of FVIII
or FIX, hemophilia is categorized as severe (<1%), moderate (1–5%),
or mild (6–40%). The cornerstone of hemophilia treatment is re-
placement therapy with FVIII/FIX concentrates and—recommended
by the World Health Organization—treatment with prophylaxis in
severe hemophilia (Andersson et al., 2017; Manco‐Johnson et al.,
2007). The main complication of replacement therapy is the devel-
opment of anti‐FVIII/FIX antibodies (inhibitors), which are able
to neutralize the clotting activity of therapeutic clotting factors
(Gouw et al., 2013).
Since the F8/F9 variant type is the main determinant of plasma
levels of FVIII or FIX, respectively, and disease severity, the analysis
of the F8 or F9 gene variant in hemophilia patients and their families
has become standard in hemophilia treatment centers in recent
years. Knowledge of the variant allows genetic counseling and pro-
vides information on the risk of inhibitor development. In addition,
information on clotting assays discrepancies, and in mild hemophilia
A, the probability of a therapeutic response to DDAVP, can be re-
trieved (Goodeve & Peake, 2003; Seary et al., 2012). Sporadic cases,
that is, with no known family history of hemophilia, account for ap-
proximately 30% of all cases when combining anamnestic data and
haplotyping to reveal variants identical to descent (Halldén et al.,
2012; Ljung et al., 1990). If hemophilia is diagnosed for the first time
in a patient, studies show that new variants are found in around
70–80% of the mothers of these index cases (Ljung et al., 1991;
Martensson et al., 2016).
Currently, direct gene sequencing either through Sanger or next‐
generation sequencing (NGS) methodologies is the predominant
technique for the testing of single nucleotide variants and small in-
sertions and deletions (Gomez & Chitlur, 2013). Nowadays, copy
number variant analysis for large deletions and duplications is per-
formed by NGS or complementary technologies such as array com-
parative genomic hybridization and multiplex ligation‐dependent
probe amplification. For the F8 intron 22 inversion, Southern blot,
long‐range PCR, and inverse PCR protocols are used, while for the F8
intron 1 inversion, a PCR‐based method is the standard technique.
The most common variant causing severe hemophilia A is intron 22
inversion in F8 affecting approximately 40% of the patients but to-
day a broad spectrum of more than 2000 variants causing hemophilia
A and more than 1000 variants causing hemophilia B are described in
FVIII or FIX variant databases, such as the American CDC Hemo-
philia Mutation Project databases CHAMP/CHBMP (https://www.
cdc.gov/ncbddd/hemophilia/champs.html) or the European EAHAD
Coagulation Factor Variant Databases (http://dbs.eahad.org), to
which F8 and F9 gene variants from all over the world are reported
voluntarily by laboratories and clinicians (Li et al., 2013; Payne et al.,
2013). The variant types in hemophilia cover a broad spectrum: in
addition to the F8 gene‐specific inversion 22 and inversion 1, sub-
stitutions, deletions, duplications, and complex variants are found
causing missense, nonsense, frameshift, deletion/insertion/duplica-
tion in frame, splice site variants and promotor variants. Usually, new
variants are crosschecked with the above‐named hemophilia variant
databases, such as the European Coagulation Factor Variant Data-
bases from EAHAD, the CDC‐based CHAMP/CHBMP or Human
Gene Mutation database (HGMD), which collect a large number of
published gene alterations. In these databases, additional informa-
tion about the number of patients with each reported variant and
clinical information on severity of the disease, factor levels, and in-
hibitor development on every reported patient may be available
(Li et al., 2013; McVey et al., 2020; Payne et al., 2013).
The clinical interpretation of a new or an unpublished genetic
variant in the F8 or F9 genes, as well as other genes, should be based
on guidelines published by the American College of Medical Genetics
and Genomics and the Association for Molecular Pathology (Richards
et al., 2015). International F8/F9 gene variant databases assist effec-
tive variant classification, especially when it is possible to combine
such data with phenotypic and pedigree information. Various in silico
prediction programs developed for missense or splice site variants
may be helpful but the provided information should be interpreted
with caution. When predicting the pathogenicity of a gene variant it is
recommended to combine several prediction programs (Richards et al.,
2015). Recently, a guideline specific for genetic analysis in bleeding
disorders has been published (Gomez et al., 2019). In addition to he-
mophilia variant databases, the presence of a variant in a reference
sequencing database of normal individuals is important and can be
evidence of nonpathogenicity. These resources include the 1000
genomes, gnomAD, dbSNP, and the NHLBI exome sequencing project.
The PedNet Registry contains prospective data on children less
than 18 years with hemophilia A or B born since January 1, 2000 who
are followed up regularly in 31 hemophilia centers in 18 countries in
Europe, Canada, and Israel. More than 2100 patients were included by
2019 and the F8/F9 gene variant reported in 85% of the cases (Fischer
et al., 2014). The purpose of the Registry is to promote and facilitate
research and development of care in this large unselected patient
population. The aim of this paper is to report all new F8/F9 variants
with clinical information on severity, factor level and inhibitor for-
mation found in the PedNet Registry not previously published or
known in hemophilia variant databases after reevaluation of the re-
ported variant using the ACMG criteria of pathogenicity.
2 | METHODS
2.1 | The PedNet cohort
Data were retrieved from the “PedNet Registry,” a database which is
owned and administered by the “PedNet Haemophilia Research
Foundation,” consisting of 31 international hemophilia treatment
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centers in 18 countries and registered at ClinicalTrials.gov at
NCT02979119. A complete list of PedNet members is added in the
Appendix. Approval for data collection was obtained from each
center's ethical review board, and written informed consent was
obtained from the parents or guardians of all participants, in ac-
cordance with the Declaration of Helsinki.
2.2 | Subjects
All patients with either hemophilia A or B, registered in the PedNet
Registry by January 1, 2018 (n = 1967) were included. Data on pa-
tients’ demographics, type and severity of hemophilia, and family
history of hemophilia were collected. Reports on genotyping from
the respective local genetic laboratories were collected from each
single center.
2.3 | Nomenclature
All reports were then classified uniformly by a central genetic la-
boratory according to the recommendations of the Human Genome
Variation Society (HGVS). The local laboratories predominantly used
conventional Sanger sequencing of F8 and F9 genes and conventional
analysis for inversions 22 and inversion 1 in the F8 gene. Variant
nomenclature was based on the following NCBI RefSec accession
numbers and confirmed by Alamut and VariantValidator: F8:
NM_000132.3; NG_011403.1; NP_000123.1 and F9: NM_000133.3;
NG_007994.1; NP_000124.1 and GRCh37 genome build. All variants
were cross‐checked with the CDC‐based databases CHAMP and
CHBMP, the EAHAD F8/F9 databases and the HGMD and a litera-
ture search on June 1, 2020, and only variants not described in these
databases or published in a scientific journal searchable on Medline
were included in this manuscript, referred to as “novel variants.”
Therefore, known polymorphisms or synonymous variants reported
in patients with novel variants are not included in this analysis.
2.4 | Phenotype of hemophilia
The PedNet Registry follows the international classification for
hemophilia valid when the Registry was initiated (i.e., severe form
FVIII/FIX <1%, moderate 1–5%, and mild with 6–25%) and not the
present classification where the mild form is defined as 6–40%
(Blanchette et al., 2014). FVIII/FIX levels were measured at each
participating center according to local standards. Both chromogenic
and one‐stage assay methods were accepted.
2.5 | Inhibitors
All patients in the PedNet Registry were included with baseline in-
formation at birth and their data were updated annually with regard
to inhibitor status and exposure days up to the age of 18 years.
Children included in this study were born between 2000 and 2017.
Of the 97 patients included, 92 attained more than 50 exposure days
to FVIII/IX concentrates. Inhibitors were divided into low‐and high‐
titer inhibitors, defined as ≤5 Bethesda Units (BU) and more
than 5 BU, respectively, according to international guidelines
(Blanchette et al., 2014). In this study, inhibitors were reported for
the new variants to support clinical information on this specific
variant.
2.6 | Classification of reports on genotypes
In line with the established databases of CHAMP, CHBMP, and
EAHAD, we used the following classifications:
The variant type in F8 was classified as inversion 22, inversion 1,
substitution, deletion, duplication, insertion, polymorphism, or com-
plex variant.
The variant type in F9 was classified as substitution, deletion,
duplication, insertion, polymorphism, or complex variant.
The molecular consequence was reported in both F8 and F9 as
missense, nonsense, frameshift, large deletion/insertion/duplication
(>50 base pairs), small deletion/insertion/duplication (<50 base
pairs), stop gain, in frame, silent variant, splice site variant, and
promotor variant.
2.7 | In silico analyses
The deleterious effects of missense variants were assessed with ALA-
MUT VISUAL (http://www.interactive-biosoftware.com/alamut-visual/),
a web‐based tool, which allows simultaneous analysis by POLYPHEN‐2
(http://genetics.bwh.harvard.edu/pph2), SIFT (http://sift.bii.a-star.edu.sg),
MutationTaster (http://www.mutationtaster.org), and Align GVGD
(http://agvgd.hci.utah.edu/agvgd_input.php) and links to the databases
ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/) and gnomAD (https://
gnomad.broadinstitute.org/).
Variants at splice junctions were evaluated with
ALAMUT VISUAL v.2.8.1 (http://www.interactive-biosoftware.
com/alamut-visual/), which allows a simultaneous analysis with
the programs SPLICE SITE FINDER‐LIKE, MAXENT SCAN,
NEURAL NETWORK SPLICE SITE, GENESPLICER, and HUMAN
SPLICING FINDER. These tools were used together in ac-
cordance with guidelines for using prediction methods (Niroula &
Vihinen, 2016). Missense variants close to splice sites underwent
splice site prediction, too. If three or more of four prediction
programs predicted that the variant under consideration was
deleterious, it was accepted as a supporting criterion PP3
according to the ACMG guidelines. If three or more prediction
programs predicted a benign variant, BP6 was used as the cri-
terion. For splice site variants, four out of five prediction pro-
grams had to be significant to be accepted as a PP3 or a BP6
criterion, respectively.
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2.8 | Classifying of new variants using the ACMG's
criteria of pathogenicity
All new variants were classified using the published criteria of
pathogenicity of the ACMG. For null variants the criterion PVS1 was
used. The criterion PS3 was used for all patients, since well‐
established functional studies on FVIII or IX were available in all
included variants, which are both validated, reproducible and robust
in a clinical diagnostic laboratory setting and are specific for hemo-
philia. All reported new variants fulfilled criterion PM2 since no allele
frequency was reported in gnomAD v2.1.1 (Karczewski et al., 2020).
Criterion PM5 was used if a missense change at an amino acid re-
sidue where a different missense change determined to be patho-
genic had been seen before. Criterion PP4 was used for all included
variants since hemophilia has a single genetic etiology and a clear
patient phenotype.
3 | RESULTS
Overall, 1967 patients from the PedNet Registry were included in
the study. Of these, 1681 patients had a report on genotyping in the
Registry (85.5%). Out of 1681 patients with hemophilia A or B, with
all severities, 97 patients had 88 novel variants, of which 86 were
classified as pathogenic or likely pathogenic: 69 causing hemophilia A
and 17 hemophilia B; one variant in F8 and one variant in F9 gene
were classified as variants of unknown significance; no benign or
likely benign variants were found in the reported variants. Of the 86
likely disease‐causing variants, 78 represent new unique variants
present in only one patient. Eight variants were present in ≥2
patients; all of which were found in patients who were related family
members with the same severity of hemophilia (e.g., brother and
cousin). As expected, the majority of the new variants found were
located in exon 14 in the F8 gene and in exon 8 in the F9 gene.
3.1 | F8—hemophilia A
In hemophilia A (n = 70), 39 of the new variants were substitutions,
25 were deletions, two were complex variants, three were duplica-
tions and one was an insertion (see Table 1). In mild and moderate
hemophilia A, all new variants were “missense.” Table 1 provides
more detailed information on variant type and molecular con-
sequence in the whole hemophilia A cohort.
Table 2 shows all null variants (n = 39) including nonsense var-
iants, complex variants, duplications, insertions, and deletions found
in patients with severe hemophilia. A total of 37 variants fulfilled
Class 5 (pathogenic) in the ACMG classification; two variants—one
deletion with small structural change in‐frame and a duplication
were classified as Class 4 (likely pathogenic).
Substitutions resulting in missense (Table 3) or at splice sites
(Table 4) underwent in silico analysis with prediction programs, as de-
scribed above. A total of 20 substitutions were classified as pathogenic
(Class 5) and three as likely pathogenic (Class 4). Of eight splice site
variants, seven were classified as pathogenic (Class 5) and one as a
variant of unknown significance with contradicting criteria (PS3, PM2,
PP4, and BP4). Inhibitors were diagnosed in 18/70 patients with hemo-
philia A with novel variants, all found in patients with the severe form of
the disease, with the exception of p.Glu409Lys found in two related
patients with moderate hemophilia, both of whom developed inhibitors.
TABLE 1 Type and molecular consequence of novel variants and phenotypic severity in hemophilia A











Substitution Missense 23 23 12 3 8
Nonsense 11 11 11 0 0
Splice site 5 5 5 0 0
Deletion Large structure
change (>50 bp)
1 1 1 0 0
Small structure change
(<50 bp, in frame)
1 1 1 0 0
Frameshift 19 19 19 0 0
Splice site 3 2 2 0 0
Stop gain 1 1 1 0 0
Duplication Frameshift 2 2 2 0 0
Large structural
change (>50 bp)
1 1 1 0 0
Insertion Frameshift 1 1 1 0 0
Complex Frameshift 2 2 2 0 0
Total no. variants 70 69 58 3 8
Abbreviations: ACMG, American College of Medical Genetics and Genomics; FVIII, Factor VIII.
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3.2 | Hemophilia B
In hemophilia B patients, in total 18 new variants were found and 17
calssified as pathogenic or likely pathogenic (Table 5): 12 in patients
with severe, three with moderate, and two with mild hemophilia B.
Table 6 shows that all null variants (n = 12) including nonsense
variants, duplications, insertions, and deletions were classified as
Class 5 (pathogenic) and were found in patients with severe hemo-
philia B with the exception of a patient with the moderate form who
had a duplication causing frameshift.
Table 7 shows the substitutions leading to missense; all under-
went in silico analysis with prediction programs, as described above,
before classification. Of seven missense variants, five were classified
as pathogenic (Class 5), one as likely pathogenic (Class 4), and one
variant as a variant of unknown significance (Class 3), reported in
Table 7.
In total, 16 variants in hemophilia B fulfilled Class 5 (pathogenic)
in the ACMG classification, one variant Class 4 (likely pathogenic),
and one as a variant of unknown significance with contradicting
criteria (PS3, PM2, PP4, and BP4). One patient with a nonsense
variant had developed an inhibitor (Table 6).
4 | DISCUSSION
Variant analysis in hemophilia has become a standard procedure
over the years, confirming suspected hemophilia, making carrier di-
agnosis possible, and enabling the identification of variants with in-
creased risk for the development of inhibitors. In this study
encompassing data from 1681 children included in the PedNet
Registry with hemophilia A or B, we report 88 novel variants in the
F8 and F9 genes not previously reported in the HGMD or CHAMP,
CHBMP, and EAHAD hemophilia variant databases by June 1, 2020.
The novel variants were, as expected, frequently found in exon 14 of
the F8 gene and exon 8 in the F9 gene, since both are the largest
exons in F8 and F9, respectively. No “hotspot” was identified, and the
novel variants were of all types following the general spectrum seen
in hemophilia A and B. This is in line with a report from Johnsen et al.
(2017) in which 3000 hemophilia patients were investigated with
NGS and 285 new variants were found in all variant types and F8 or
F9 loci.
Of 88 novel variants, 80 could be ACMG classified as pathogenic
(Class 5), six as likely pathogenic (Class 4), and two as variants of
unknown significance (Class 3). As hemophilia is an X‐linked single‐
gene disease with a well‐established measurable phenotype, a var-
iant is often found fulfilling Class 4 or 5 criteria for pathogenicity.
Also in former studies, probable disease‐causing variants are iden-
tified in approximately 95% of hemophilia A cases and in almost all
patients with hemophilia B (Swystun & James, 2017). However, most
likely not all variants considered to be “polymorphisms” or “not
disease causing” in the F8 or F9 genes were included in the genetic
reports reviewed in this paper. Following guidelines, it is re-
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clinician, and variants of unknown significance only if no other cause
for the disease was found (Wallis et al., 2013). Thus, it is likely that
more than the reported variant was found in some patients in the
local laboratory, but only those variants interpreted as being sig-
nificant were reported to the PedNet Registry.
One of the interpretation criteria in the ACMG classification is
computational analysis with in silico analysis (PS3/BP4). Two of the
presented variants were classified as a VUS due to contradicting in
silico prediction. It is a known phenomenon that in silico analysis—
despite being combined of several algorithms—can be nonconclusive
and should be seen as only one step in categorizing variants as de-
scribed by the ACMG (Niroula & Vihinen, 2016). Differential diag-
nosis should also be considered, for example, von Willebrand disease
variants causing low FVIII levels.
While the ACMG guidelines' interpretation of variants offers a
very useful, well‐defined set of criteria in international consensus,
further interpretation of the criteria can be required. Several pub-
lications have discussed how to interpret different criteria, for ex-
ample, the US Sequence Variant Interpretation working group
(https://www.clinicalgenome.org/working-groups/sequence-variant-
interpretation/) or the UK Association for Clinical Genomic Science
(https://www.acgs.uk.com/news/acgs-best-practice-guidelines-for-
variant-classification-2019/). For bleeding disorders, a UK guideline
by Gomez et al. (2019) is available. However, the interpretation of
variants remains complex, and in 2017, evaluations from the
National External Quality Assessment Service (UK) showed that la-
boratories rated new variants in different ways, in some cases dif-
fering between Classes 2 and 5. In another study, concordance of
variant interpretation was only 34% in nine laboratories using both
in‐house criteria and ACMG guidelines, but this figure was raised
after detailed review and consensus discussions to 71% (Amendola
et al., 2016). As hemophilia is an X‐linked disease with well‐defined
phenotypes and genotypes, phenotype association can be less de-
manding, but disease‐specific interpretations and consensus discus-
sions may be required to improve the final classification of the
ACMG criteria.
Since the data were retrieved from the PedNet hemophilia Reg-
istry with 31 centers reporting over the last two decades, reporting of
variants may differ between different laboratories over time, which is
one of the limitations in our study. To ensure as high‐quality reporting
as possible in the Pednet Registry, all reports were reevaluated ret-
rospectively and updated with HGVS nomenclature and classification
in 2018–2020 by a genetic laboratory technician and two MDs (Lund
University, Malmö/Lund, Sweden). A regular update of genetic reports
is planned for the PedNet Registry and all new reports to be included
are reevaluated continuously. The EAHAD database recently pre-
sented their new database with new data, analysis tools and common
database architecture with new interfaces and filters that conform to
HGVS guidelines and variants are now reported in relation to
reference sequences (RefSeq; McVey et al., 2020). In addition, the
EAHAD database plans to update annually.
While hemophilia genetic variant databases are very useful, it
should be noted that they have certain limitations. Reporting in he-
mophilia variant databases, such as EAHAD, CHAMP, and CHBMP, is
voluntary and reports are submitted from a wide spectrum of clinicians
and laboratories, which makes the investigation of hemophilia
population‐based frequencies difficult. Also, the update of these re-
gistries may differ. To be sure that a variant is novel, a literature search
has to be performed additionally. Entries to the HGMD are based on
published variants; however, not all new variants are published. The
definition of variant type and effect or molecular consequence differs
between databases and publications and adaptations are needed for
comparisons. There is no requirement to classify variants by the ACMG
guidelines and to use prediction programs of missense or splice site
variants when reporting such a variant, even if most new reports follow
these standards today. Also, the type and amount of phenotypic and
clinical data captured in these resources varies. As discussed by Gomez
et al. (2019), some databases allow multiple reports of the same variant
while others only report a single, usually the first, occurrence. This
raises the possibility of the same variant being classified inconsistently
depending on the sources of evidence used. Most probably, some var-
iants in the hemophilia databases reported are variants not causing
TABLE 5 Type and molecular
consequence of novel variants and

















Substitution Missense 7 6 2 2 2
Nonsense 3 3 3 0 0
Deletion Frameshift 4 4 4 0 0
Duplication Frameshift 2 2 1 1 0
Small del/ins/
dup (<50 bp, in
frame)
1 1 1 0 0
Insertion Frameshift 1 1 1 0 0
Total 18 17 12 3 2
Abbreviations: ACMG, American College of Medical Genetics and Genomics; FIX, Factor IX.
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hemophilia, which was also suggested by another group, finding 11
earlier reported variants unlikely to cause hemophilia (Johnsen
et al., 2017).
In 19 variants, inhibitor development was reported: 18 variants in
patients with hemophilia A (18/70; 25.7%), and one in a patient with
severe hemophilia B (1/19; 5.3%). Although the new variants only
represent a subgroup of our population‐based registry, this follows the
expected rate of inhibitor formation for patients with hemophilia A
and B. (Gouw et al., 2012). The risk of inhibitor development asso-
ciated with a certain variant is very useful in clinical decision making
on the type of prophylaxis or therapy in the more severe forms but
also in the milder forms of the diseases (Mahlangu et al., 2018).
In conclusion, we report 88 novel variants in the F8 and F9 genes
of which 86 are concluded to cause hemophilia A or B, according to
the ACMG classification. The strength of our study is the uniform
collection of variants in a large well‐defined cohort with regular re-
evaluation of genetic reports and alignment to international guide-
lines. This study also demonstrates the value of reevaluating and
updating earlier genetic reports in the light of changed nomen-
clature, new classification criteria, such as ACMG guidelines, new in
silico prediction programs, new or updated population databases and
disease‐specific databases, such as EAHAD and CHAMP.
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